IP Library Granted Patent US 9,694,022
Granted Patent B2
US 9,694,022 · App. 15/335,381 · Granted Jul 4, 2017

Osteoclast inhibitors for knee conditions

Inventor: Herriot Tabuteau (New York, NY)
Assignee: ANTECIP BIOVENTURES II LLC
A61K31/663A61K9/0019A61K9/0053A61K9/0056A61K9/2004A61K31/573A61K31/675A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,694,022
App. No.
15/335,381
Granted
Jul 4, 2017
Kind
B2
Abstract

Oral dosage forms of osteoclast inhibitors, such as nitrogen-containing bisphosphonates, can be used to treat or alleviate pain or related conditions.

Claims (32)

1. A method of treating an osteoarthritis of the knee comprising:

a. selecting a patient having an osteoarthritis of the knee and OARSI Grade 0 or Kellgren and Lawrence Grade 0 or Grade 1 of joint space narrowing; and

b. administering an inhibitor of osteoclast activity to a human being in need thereof, wherein the inhibitor of osteoclast activity is olpadronic acid, minodronic acid, incadronic acid, or alendronic acid.

2. The method of claim 1 , wherein about 1 mq to about 500 mq of the inhibitor of osteoclast activity is administered within a period of two months.

3. The method of claim 2 , wherein the inhibitor of osteoclast activity is olpadronic acid.

4. The method of claim 2 , wherein the inhibitor of osteoclast activity is minodronic acid.

5. The method of claim 2 , wherein the inhibitor of osteoclast activity is incadronic acid.

6. The method of claim 2 , wherein the inhibitor of osteoclast activity is alendronic acid.

7. A method of claim 1 , wherein the inhibitor of osteoclast activity is administered at least twice, and about every three months, or more frequently.

8. The method of claim 1 , wherein the inhibitor of osteoclast activity is administered orally.

9. The method of claim 1 , wherein the inhibitor of osteoclast activity is administered intravenously.

10. The method of claim 1 , wherein the inhibitor of osteoclast activity is administered as a salt.

11. The method of claim 1 , wherein the inhibitor of osteoclast activity is administered once weekly for a period of six weeks.

12. The method of claim 8 , wherein the each oral dose comprises about 10 mg to about 300 mg of the inhibitor of osteoclast activity.

13. The method of claim 8 , wherein the human being to which the inhibitor of osteoclast activity is administered does not eat food or drink beverage for at least 30 minutes after the inhibitor of osteoclast activity is administered.

14. A method of treating osteoarthritis of the knee comprising administering an inhibitor of osteoclast activity to a human being in need thereof, wherein the inhibitor of osteoclast activity is olpadronic acid, minodronic acid, incadronic acid, or alendronic acid, and wherein the inhibitor of osteoclast activity is administered at least twice, and the inhibitor of osteoclast activity is administered about every three months, or more frequently.

15. The method of claim 14 , wherein the inhibitor of osteoclast activity is administered orally.

16. The method of claim 14 , wherein the inhibitor of osteoclast activity is co-administered with a steroid.

17. The method of claim 16 , wherein the steroid is prednisone.

18. The method of claim 14 , wherein the inhibitor of osteoclast activity is olpadronic acid.

19. The method of claim 14 , wherein the inhibitor of osteoclast activity is minodronic acid.

20. The method of claim 14 , wherein the inhibitor of osteoclast activity is incadronic acid.

21. The method of claim 14 , wherein the inhibitor of osteoclast activity is alendronic acid.

22. The method of claim 14 , wherein the inhibitor of osteoclast activity is administered daily.

23. The method of claim 14 , wherein the inhibitor of osteoclast activity is administered weekly.

24. The method of claim 14 , wherein the inhibitor of osteoclast activity is administered monthly.

25. The method of claim 14 , wherein the inhibitor of osteoclast activity is administered intravenously.

26. The method of claim 14 , wherein the inhibitor of osteoclast activity is administered as a salt.

27. The method of claim 16 , wherein the dose of the steroid is about 1 to about 500 mg.

28. The method of claim 16 , wherein the dose of steroid is about 5 mg to about 25 mg.

29. The method of claim 15 , wherein the each oral dose comprises about 1 mg to about 100 mg of the inhibitor of osteoclast activity.

30. The method of claim 14 , wherein about 40 mg to about 400 mg of the osteoclast inhibitor is administered within a period of one month.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 5, 2017
From: TABUTEAU, HERRIOT
To: ANTECIP BIOVENTURES II LLC
Reel/Frame 040866/0742 →
Continuity (22)
Continuation 14967234 · Dec 11, 2015
Continuation 14605822 · Jan 26, 2015
Continuation 14604524 · Jan 23, 2015
Continuation In Part 14536526 · Nov 7, 2014
Continuation In Part 14446184 · Jul 29, 2014
Division 14288716 · May 28, 2014
Continuation In Part 14279229 · May 15, 2014
Continuation 14063979 · Oct 25, 2013
Continuation 13894274 · May 14, 2013
Provisional Application 61933608 · Jan 30, 2014
Provisional Application 61803721 · Mar 20, 2013
Provisional Application 61767647 · Feb 21, 2013
Provisional Application 61767676 · Feb 21, 2013
Provisional Application 61764563 · Feb 14, 2013
Provisional Application 61762225 · Feb 7, 2013
Provisional Application 61655541 · Jun 5, 2012
Provisional Application 61655527 · Jun 5, 2012
Provisional Application 61654383 · Jun 1, 2012
Provisional Application 61654292 · Jun 1, 2012
Provisional Application 61647478 · May 15, 2012
Provisional Application 61646538 · May 14, 2012
Related Publication 20170042914A1 · Feb 16, 2017